Results 141 to 150 of about 92,043 (285)

Cochlear Implantation in Autoimmune Inner‐Ear Disease: Outcome and Patient‐Reported Benefit

open access: yesThe Laryngoscope, EarlyView.
This study demonstrates that patients with secondary autoimmune inner‐ear disease (AIED) achieve significant improvements in speech perception and quality of life following cochlear implantation. Although AIED patients may show slightly lower performance in noisy environments compared to controls, their subjective hearing benefit converges with matched
Merete Hartmann   +4 more
wiley   +1 more source

Resolution of Levodopa/Dopa‐Decarboxylase Inhibitor—Associated Microscopic Colitis with Subcutaneous Foslevodopa/Foscarbidopa: A Case Series and Review of the Literature

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Microscopic colitis (MC) typically presents with chronic, non‐bloody watery diarrhea. Diagnosis requires endoscopy with colonic mucosal biopsies. The etiology is multifactorial, with several medications implicated, although only a few cases have been attributed to oral levodopa/dopa‐decarboxylase inhibitor (LDDCI) therapy.
Romana Hintner   +10 more
wiley   +1 more source

Prediction of deep remission through serum TNF-α level at 1 year of treatment in pediatric Crohn’s disease

open access: yesScientific Reports
A pilot study investigated the cytokine profile (IL-6, TNF-α, IL-17 A, and IL-10) at diagnosis, affecting infliximab (IFX) trough levels (TLs) in pediatric patients with Crohn’s disease (CD).
Seon Young Kim   +6 more
doaj   +1 more source

Successful treatment of therapy-resistant metastatic Crohn's desiase with infliximab [PDF]

open access: yes, 2004
CASTIGLIONE, FABIANA   +5 more
core   +1 more source

Single‐center experience of the Crohn's disease exclusion diet in the United States: A retrospective study

open access: yesNutrition in Clinical Practice, EarlyView.
Abstract Background The Crohn's Disease Exclusion Diet (CDED) offers a dietary means of inducing and maintaining remission for patients with Crohn's disease (CD). Descriptions of efficacy have emerged primarily from Israel, Europe, and Canada. Here, we offer real‐world experience, from a tertiary care center in the United States. Methods We conducted a
Mayah Greenfield   +5 more
wiley   +1 more source

Mesenchymal stromal cell therapy for rheumatoid arthritis: Long‐term efficacy, safety, and mechanistic insights

open access: yesRheumatology &Autoimmunity, EarlyView.
Graphical abstract summarizing the multifactorial pathogenesis of rheumatoid arthritis (RA) and the therapeutic potential of mesenchymal stromal cell (MSC) therapy. MSCs provide promising benefits through their immunomodulatory properties, low immunogenicity, ability to promote tissue repair, and multi‐lineage differentiation, presenting a potential ...
Yingjia Chen   +6 more
wiley   +1 more source

Exploring market dynamics of biological including biosimilar treatments for retinal diseases in Europe: An interrupted time‐series analysis

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose To assess the impact of biosimilar ranibizumab and on‐patent faricimab market entry on pricing and utilization trends and describe national variation in off‐label bevacizumab use in Europe. Methods Interrupted time series analysis of quarterly sales data (Q1 2018–Q2 2024) in 11 European countries evaluated ranibizumab utilization and ...
Elif Car   +3 more
wiley   +1 more source

Diagnostic Impact of Liver Biopsy Among Antinuclear Antibody Positive Individuals With Mild Liver Enzyme Elevation

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
In ANA‐positive patients with suspected autoimmune hepatitis (AIH), liver biopsy rarely altered therapeutic management when alanine aminotransferase (ALT) was below 101 U/L and cirrhosis was absent. These findings suggest that biopsy may be safely deferred in this low‐risk group.
David Mehdi Asgher Niazi   +8 more
wiley   +1 more source

One‐Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real‐World GETAID Study

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
In a real‐world cohort of patients with highly refractory perianal Crohn's disease, upadacitinib induced clinical remission at 12 months in 26% of patients with fistulizing disease and 25% of those with isolated anal ulcerations. ABSTRACT Introduction Upadacitinib (UPA) is effective for treating luminal Crohn's disease (CD), but data on perianal CD ...
Nicolas Richard   +13 more
wiley   +1 more source

A Care Pathway for the Treatment of IBD Reduces Healthcare Costs and Is Cost‐Effective: Results of the Multicentre IBD Value Study

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
This study provides real‐world evidence that implementing an advanced therapy care pathway for patients with IBD leads to significant healthcare cost savings without compromising quality of life. These findings support broader implementation of care pathways in the management of patients with chronic conditions to optimise care delivery and resource ...
Elyke H. Visser   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy